Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742986 · ClinicalTrials.gov registry record · Phase 2
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03742986 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 8 participants.
The verdict
NCT03742986, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
Interventions
- DRUG Nivolumab 360mg
- DRUG Paclitaxel 80mg/m^2
- DRUG Doxorubicin 60mg/m^2
- DRUG Cyclophosphamide 600mg/m^2
- DRUG Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03742986
The ClinicalTrials.gov registry entry for NCT03742986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab 360mg is the first listed.
NCT03742986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03742986 about?
NCT03742986 is a clinical study titled "Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)". Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
What is the current status of trial NCT03742986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2019-05-02. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT03742986?
The interventions under investigation include: Nivolumab 360mg (DRUG), Paclitaxel 80mg/m^2 (DRUG), Doxorubicin 60mg/m^2 (DRUG), Cyclophosphamide 600mg/m^2 (DRUG), Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT03742986?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.